St. Joseph’s Candler Hospital

Recent papers from St. Joseph’s Candler Hospital

1. Genetic Correlates of Malignant Behavior in Aggressive Pituitary TumorsEuropean Journal of Endocrinology · 2026
2. Sunitinib in Patients With Various Solid Tumors With FGFR1 / 2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJCO Precision Oncology · 2026
3. Recurrent Acute Limb Ischemia Secondary to Tumor Embolism: A Rare Malignant ManifestationAnnals of Vascular Surgery - Brief Reports and Innovations · 2026
4. 71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trialESMO Open · 2026
5. Adverse Events in a Randomized Trial Comparing Radiotherapy with or without Olaparib for Inflammatory Breast CancerInternational Journal of Radiation Oncology*Biology*Physics · 2026
6. Sustainable microbial production of retinol in Yarrowia lipolytica: From strain engineering to formulationNew Biotechnology · 2026
7. Breaking Bad News: A Simulation-Based Training Program for OB/GYN ResidentsMedEdPORTAL · 2026
8. Using WCS-GNB for intrusion detection: improving Gaussian Naive Bayes with class-specific weights and validating against different machine learning modelsFrontiers in Computer Science · 2026
9. Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialGynecologic Oncology · 2026
10. Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Journal of Clinical Oncology · 2026
11. Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.Journal of Clinical Oncology · 2026
12. Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).Journal of Clinical Oncology · 2026
13. Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With SepsisPharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2026
14. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJCO Precision Oncology · 2026
15. Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerJAMA Network Open · 2026
16. 799: Association Between Subcutaneous Medication Administration and Icu DeliriumCritical Care Medicine · 2026
17. Dalbavancin Utilization Registry Investigating Value and Efficacy (DRIVE)Infectious Diseases in Clinical Practice · 2026
18. I Highly Recommend this Candidate: Survey of PGY1 program directors regarding residency letter recommendation levelsAmerican Journal of Pharmaceutical Education · 2026
19. Examining individual serotonin and norepinephrine reuptake inhibitors and fall-related hospitalizations in older adultsMental Health Clinician · 2026
20. Impact of a Pharmacist-Driven Penicillin Allergy De-Labeling Service (PADLS) on Hospitalized PatientsPharmacy · 2026